Abstract
p63, known to play a role in development, has more recently also been implicated in cancer progression. Mutations in p63 have been shown to be responsible for several human developmental diseases. Differential splicing of the p63 gene gives rise to p63 isoforms, which can act either as tumor suppressors or as oncogene. In this report, we studied the effects of naturally occurring TAp63γ mutants on the regulation of p53/p63 and p63 specific target genes. We observed significant differences among p63 mutants to regulate the p53/p63 and p63 specific target genes. Additionally, we observed a differential effect of p63 mutants on wildtype-p63-mediated induction of p53/p63 and p63 specific target genes. We also demonstrated that these mutants differentially regulate the binding of wildtype p63 to the promoter of target genes. Furthermore, the effects of these mutants on cell death and survival were consistent with their ability to regulate the downstream targets when compared to wildtype TAp63γ. In summary, our data demonstrate that p63 mutants exhibit differential effects on p63 and p53/p63 specific target genes and on the induction of apoptosis, and provide further insight into the function of p63.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A . p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708–713.
Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714–718.
Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215–221.
Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4:839–843.
Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305–316.
Rinne T, Brunner HG, van Bokhoven H . p63-associated disorders. Cell Cycle 2007; 6:262–268.
Koga F, Kawakami S, Fujii Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003; 9:5501–5507.
Park BJ, Lee SJ, Kim JI, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000; 60:3370–3374.
Urist MJ, Di Como CJ, Lu ML, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161:1199–1206.
Wang X, Mori I, Tang W, et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002; 9:216–219.
Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363–373.
Keyes WM, Vogel H, Koster MI, et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 2006; 103:8435–8440.
Senoo M, Matsumura Y, Habu S . TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene 2002; 21:2455–2465.
Barbieri CE, Barton CE, Pietenpol JA . Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem 2003; 278:51408–51414.
Wu G, Nomoto S, Hoque MO, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003; 63:2351–2357.
Spiesbach K, Tannapfel A, Mossner J, Engeland K . TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. Int J Cancer 2005; 114:555–562.
Kim S, Han J, Kim J, Park C . Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res 2004; 64:6900–6905.
Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L . Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 2002; 22:8659–8668.
Helton ES, Zhu J, Chen X . The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem 2006; 281:2533–2542.
Gressner O, Schilling T, Lorenz K, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24:2458–2471.
Petitjean A, Cavard C, Shi H, et al. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene 2005; 24:512–519.
Osada M, Park HL, Nagakawa Y, et al. Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol 2005; 25:6077–6089.
Kommagani R, Caserta TM, Kadakia MP . Identification of vitamin D receptor as a target of p63. Oncogene 2006; 25:3745–3751.
Caserta TM, Kommagani R, Yuan Z, Robbins DJ, Mercer CA, Kadakia MP . p63 overexpression induces the expression of Sonic Hedgehog. Mol Cancer Res 2006; 4:759–768.
Shimada A, Kato S, Enjo K, et al. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 1999; 59:2781–2786.
Kirschner RD, Sanger K, Muller GA, Engeland K . Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic Acids Res 2008; 10.1093/nar/gkn132:gkn132
Nahor I, Abramovitch S, Engeland K, Werner H . The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res 2005; 15:388–396.
Sasaki Y, Ishida S, Morimoto I, et al. The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 2002; 277:719–724.
Xu Y, Chen X . Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family. J Biol Chem 2006; 281:26702–26713.
Yan W, Chen X . GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J Biol Chem 2006; 281:7856–7862.
Katoh I, Aisaki KI, Kurata SI, Ikawa S, Ikawa Y . p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 2000; 19:3126–3130.
Kunisaki R, Ikawa S, Maeda T, et al. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate. J Gene Med 2006; 8:1121–1130.
Ianakiev P, Kilpatrick MW, Toudjarska I, Basel D, Beighton P, Tsipouras P . Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. Am J Hum Genet 2000; 67:59–66.
Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416:560–564.
Gressner O, Schilling T, Lorenz K, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24:2458–2471.
Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4:321–328.
Celli J, Duijf P, Hamel BC, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99:143–153.
Li Y, Prives C . Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007; 26:2220–2225.
Flores ER . The roles of p63 in cancer. Cell Cycle 2007; 6:300–304.
Rinne T, Hamel B, van Bokhoven H, Brunner HG . Pattern of p63 mutations and their phenotypes--update. Am J Med Genet A 2006; 140:1396–1406.
Reisler TT, Patton MA, Meagher PP . Further phenotypic and genetic variation in ADULT syndrome. Am J Med Genet A 2006; 140:2495–2500.
Yang A, McKeon F . P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000; 1:199–207.
Fan TL, Hao YB, Xu PR, Hou GQ, Jiang GZ, Yang GR . TAp63gamma-induced apoptosis mediated by apoptosis inducing factor in human esophageal squamous carcinoma EC9706 cells. Zhonghua Bing Li Xue Za Zhi 2007; 36:384–389.
Kadakia M, Slader C, Berberich SJ . Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol 2001; 20:321–330.
Acknowledgements
We thank the members of the lab, Joshua DeWeese, Angela Wagner and Stefanie Lewis, for technical assistance. This work was supported in part by a grant from the NCI/NIH (CA118315-2) to MPK.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khokhar, S., Kommagani, R. & Kadakia, M. Differential effects of p63 mutants on transactivation of p53 and/or p63 responsive genes. Cell Res 18, 1061–1073 (2008). https://doi.org/10.1038/cr.2008.82
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/cr.2008.82
